# Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer

> **NCT03216343** · PHASE1 · COMPLETED · sponsor: **Chipscreen Biosciences, Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Chiauranib

## Key facts

- **NCT ID:** NCT03216343
- **Lead sponsor:** Chipscreen Biosciences, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-09
- **Primary completion:** 2022-11-04
- **Final completion:** 2023-05-15
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03216343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03216343, "Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03216343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*